CDC25B expression was moderately down-regulated when CML primary cells were treated with either imatinib or JAK inhibitor I, however showed a drastic change when a combination of the drugs were used (Fig. 6F). Here, CDC25B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.